• The Flowr Corporation (TSXV:FLWR) has received approval for an additional ten grow rooms at its Kelowna 1 facility
  • Issued by Health Canada, the approval will enable full operation at the facility
  • Brings the total number of grow rooms to 20, with potential cannabis flower output of 10,000 kg annually
  • Flowr is also installing an automated packaging line in a bid to reduce costs
  • Shares in the company are currently down 3.09 per cent to C$0.94, with a market cap of C$80.69 million

The Flowr Corporation (TSXV:FLWR) has received approval from Health Canada for an additional ten grow rooms at its Kelowna 1 facility.

With operations in Canada, Europe and Australia, the Toronto-based company grows premium cannabis flowers at state-of-the-art premises.

Receipt of the approval now means that the Kelowna 1 location is able to double its cultivation capacity to 10,000 kg each year, with a total of 20 grow rooms.

The company expects expansion to begin immediately at the 85,000 sq ft facility.

“The full licensing of Kelowna 1 is a major milestone for Flowr. For the first time since we broke ground on the facility we won’t be operating out of a construction site,” said Flowr CEO, Vinay Tolia.

“We continue to see growing demand for our premium cannabis products led by our flagship strain, Pink Kush,” he added.

Flowr’s cultivation assets are built to strict Good Manufacturing Practice (GMP) standards.

They feature proprietary designs and irrigation systems with the chief intent to produce consistent and high-quality flower.

“Furthermore,” continued Mr. Tolia, “we expect to see an improvement in operating efficiency as we reach scale coupled with the commissioning of our automated packaging line.”

The implementation of automated processes is part of Flowr’s wider initiative to reduce labor and production costs.

Shares in the company are currently down 3.09 per cent to C$0.94, with a market cap of C$80.69 million.

More From The Market Online

The Market Online’s Weekly Cannabis Report – May 24, 2024

A global cannabis stock intends to raise up to US$250 million through an at-the-market equity program to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.